• In late February and early March 2026, Ionis Pharmaceuticals reported 2025 results, received FDA Priority Review for olezarsen in severe hypertriglyceridemia, and presented new Phase 3 data for its approved hereditary angioedema therapy DAWNZERA at the AAAAI 2026 meeting in Philadelphia.
• Together, the Priority Review for olezarsen and expanded DAWNZERA data highlight Ionis’s push to turn its RNA platform into multiple commercialized cardiovascular and immunology therapies.
• We’ll now examine how the FDA’s Priority Review for olezarsen could reshape Ionis’s investment narrative and expectations for future growth.

Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

Ionis Pharmaceuticals Investment Narrative Recap

To own Ionis today, you have to believe its RNA platform can translate into multiple successful drugs while the company manages pricing, payer pressure, and sustained losses. In the near term, the FDA’s Priority Review for olezarsen in severe hypertriglyceridemia is the key catalyst, with regulatory and launch execution the biggest risks. The latest news reinforces how central olezarsen has become to Ionis’s story but does not remove the underlying pricing and margin concerns.

The olezarsen Priority Review announcement is the most directly relevant development, because it brings a clear US FDA decision date of June 30, 2026 into focus. The strong Phase 3 CORE and CORE2 data underpin the application and sharpen attention on label scope, pricing, and payer access, which sit at the heart of both the upside case and the risk of future revenue compression as Ionis targets broader sHTG populations.

Yet even with Priority Review in hand, investors should be aware that pricing pressure in larger sHTG populations could still...

Ionis Pharmaceuticals’ narrative projects $1.5 billion revenue and $241.3 million earnings by 2028.

Uncover how Ionis Pharmaceuticals' forecasts yield a $90.67 fair value, a 22% upside to its current price.

Exploring Other Perspectives

While consensus expects fast revenue growth, the most cautious analysts saw only about 3 percent annual growth to roughly US$1.0 billion by 2028, highlighting how pricing pressure and competition could weigh on the olezarsen story in very different ways once this Priority Review plays out.

Explore 4 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 20 early-stage AI stocks could fund your retirement.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.